Abstract | OBJECTIVES: METHODS: Conventional radiographs of the cervical and the lumbar spine of 33 AS patients at baseline (BL), after 2 (FU1) and after 4 yrs (FU2) of infliximab therapy were scored by the modified Stokes ankylosing spondylitis spinal score (mSASSS). Definite baseline damage was defined when at least one syndesmophyte (mSASSS >/=2) was seen. Definite radiographic progression was defined as a change from 0 or 1 to syndesmophytes or ankylosis (mSASSS >/=2). RESULTS: The mean change over 4 yrs was 1.6 +/- 2.6 mSASSS units (P = 0.001), (0.9 +/- 2.3 for BL-FU1 vs 0.7 +/- 1.6 for FU1-FU2). This is less radiographic progression in comparison with published data from the OASIS cohort (4.4 within 4 yrs). Definite radiographic progression was found in 10/33 (30.3%) patients for BL-FU2. Patients with definite damage at BL developed more chronic changes at FU2 (2.3 +/- 3.1, P = 0.003) than those with no damage at BL (0.7 +/- 1.5, P = 0.08). Four out of seven patients with no damage at BL showed radiographic deterioration after 4 yrs. The change of the mean mSASSS in comparison with BL was significantly different after 2 (P = 0.007) but not after 4 yrs of infliximab therapy. CONCLUSIONS: There is some radiographic progression after 2 and 4 yrs of infliximab therapy in AS patients. A comparison with the historical OASIS cohort suggests that infliximab may decelerate progression of structural changes. Larger studies are needed to confirm this finding.
|
Authors | X Baraliakos, J Listing, J Brandt, H Haibel, M Rudwaleit, J Sieper, J Braun |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 46
Issue 9
Pg. 1450-3
(Sep 2007)
ISSN: 1462-0324 [Print] England |
PMID | 17623745
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
- Infliximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Cervical Vertebrae
(diagnostic imaging)
- Disease Progression
- Follow-Up Studies
- Humans
- Infliximab
- Lumbar Vertebrae
(diagnostic imaging)
- Middle Aged
- Radiography
- Severity of Illness Index
- Spondylitis, Ankylosing
(diagnostic imaging, drug therapy)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|